Aveo boosted headcount sixfold in leadup to drug launch

Leading up to Aveo Oncology's first-ever FDA approval last week of a kidney cancer drug called Fotivda, the company has multiplied its headcount sixfold over the past year.

Source: bizjournals.com Health Care:Biotechnology headlines - March 15, 2021 Category: Biotechnology Authors: Don Seiffert Source Type: news